Literature DB >> 6502487

Stereospecific fluorescence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine.

C Banfield, M Rowland.   

Abstract

A stereospecific assay for the simultaneous determination of the enantiomers of warfarin and its major metabolites, 6- and 7-hydroxywarfarin and warfarin alcohols, in plasma and urine was developed. Involved in this determination was the formation of diastereoisomeric esters with carbobenzyloxy-L-proline, separation by normal-phase high-performance liquid chromatography, and detection by fluorescence after postcolumn aminolysis with n-butylamine. The determination limit for any enantiomer is in the order of 50-100 ng. The method was applied to the analysis of the enantiomers of warfarin and metabolites in plasma and urine of human subjects receiving racemic drug. The results for warfarin enantiomers are comparable with those obtained by an MS method, involving administration of a synthetic pseudoracemate [12C(R), 13C(S)]warfarin. In addition to all known metabolites, the detection of 7-R-hydroxywarfarin indicates that 7-hydroxylation is stereoselective rather than stereospecific.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6502487     DOI: 10.1002/jps.2600731017

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  15 in total

Review 1.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Primary and secondary toxicity of warfarin, sodium monofluoroacetate, and methyl parathion in mink.

Authors:  R J Aulerich; R K Ringer; J Safronoff
Journal:  Arch Environ Contam Toxicol       Date:  1987-05       Impact factor: 2.804

3.  The warfarin-cimetidine interaction: stereochemical considerations.

Authors:  S Toon; K J Hopkins; F M Garstang; B Diquet; T S Gill; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

4.  Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.

Authors:  W M Awni; Z Hussein; G R Granneman; K J Patterson; L M Dubé; J H Cavanaugh
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

5.  Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin.

Authors:  Jasper Dingemanse; Carsten Meyerhoff; Jan Schadrack
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

6.  Development of a chiral micellar electrokinetic chromatography-tandem mass spectrometry assay for simultaneous analysis of warfarin and hydroxywarfarin metabolites: application to the analysis of patients serum samples.

Authors:  Xiaochun Wang; Jingguo Hou; Michael Jann; Yuen Yi Hon; Shahab A Shamsi
Journal:  J Chromatogr A       Date:  2012-11-26       Impact factor: 4.759

7.  The measurement of warfarin enantiomers in serum using coupled achiral/chiral, high-performance liquid chromatography (HPLC).

Authors:  Y Q Chu; I W Wainer
Journal:  Pharm Res       Date:  1988-10       Impact factor: 4.200

8.  Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin.

Authors:  A Van Hecken; R Verbesselt; M Depré; T B Tjandramaga; J Angehrn; W Cawello; P J De Schepper
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Further insight into the stereoselective interaction between warfarin and cimetidine in man.

Authors:  I Niopas; S Toon; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

10.  High clearance of (S)-warfarin in a warfarin-resistant subject.

Authors:  H O Hallak; P J Wedlund; M W Modi; I H Patel; G L Lewis; B Woodruff; A A Trowbridge
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.